RT Journal Article
SR Electronic
T1 Evaluation of the effect of quit smoking with arteriosclerosis index in COPD patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P325
VO 44
IS Suppl 58
A1 Akinori Ebihara
A1 Akifumi Watanabe
A1 Asuka Nagai
A1 Rurika Hamanaka
A1 Tokuzen Iwamoto
A1 Ichiro Kuwahira
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P325.abstract
AB Background: Cardiovascular events are an important part of the comorbidities and complications in COPD patients. Analyzing the data of the ratio of serum Eicosapentaenoic Acid to Arachidonic Acid: EPA/AA and Ankle Brachial Pressure Index: ABI, which were useful as an indicator of arteriosclerosis, we evaluated change of the arteriosclerosis after quit smoking.Methods: A total of 73 subjects, male 47, female 26, were enrolled into the study after informed consents were obtained until January 2014 from May 2007 in Erimo town clinic in Hokkaido. We divided potential subjects into two groups: Group 1 had a history of COPD and sever exposure to tobacco smoke; more than 40 pack year, Group 2 had moderate exposure; more than 20 to 40 pack year. In each group, we subdivided the groups into quit smoking (G1a, G2a), and continued smoking (G1b, G2b). We had checked patients who had a previous follow-up 1 year or more; we analyzed the effect of quit smoking in atherosclerosis.Results: G1a was 12 subjects (m 8, f 4), G2a was 17(11,6), and G1b was 26(20,6), G2b was 18(8,10), respectively. ABI in G1a:G1b 0.82±0.24(±SD): 0.84±0.35, G2a:G2b 0.83±0.18: 0.83±0.34, EPA / AA in G1a:G1b 0.42±0.16: 0.43±0.14, G2a:G2b 0.42±0.14: 0.43±0.12, max IMT in G1a:G1b 1.37 ± 0.18: 1.34 ± 0.19,G2a:G2b1.21 ± 0.17: 1.24 ± 0.16. G1a was tendency improvement in ABI and EPA/AA, when compared with G1b. However there was no significant difference in max IMT. G2a demonstrated slightly improvement max IMT which compared with G2b, but there was no difference in the other data.Conclusion: We considered quit smoking will lead to the improvement of arteriosclerosis in COPD patients.